跳到主要內容

臺灣博碩士論文加值系統

(44.192.20.240) 您好!臺灣時間:2024/02/24 00:40
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:江依霖
研究生(外文):Chiang, Yi-Lin
論文名稱:我國生物技術在製藥工業應用之探討
論文名稱(外文):The Study of Applying Biotechnology in Pharmaceutical Industry in Taiwan
指導教授:吳青松吳青松引用關係
指導教授(外文):Ching-Sung Wu, Ph. D.
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:國際企業學研究所
學門:商業及管理學門
學類:企業管理學類
論文種類:學術論文
論文出版年:2001
畢業學年度:89
語文別:英文
論文頁數:128
中文關鍵詞:生物技術製藥工業
外文關鍵詞:BiotechnologyPharmaceutical Industry
相關次數:
  • 被引用被引用:7
  • 點閱點閱:394
  • 評分評分:
  • 下載下載:53
  • 收藏至我的研究室書目清單書目收藏:3
論文摘要
國立台灣大學九十學年度第二學期國際企業學研究所碩士論文摘要
論文題目:我國生物技術在製藥工業應用之探討
指導教授:吳青松 博士
研究生:江依霖 撰
有鑑於製藥工業發展面臨技術升級的瓶頸,加上近年來生物技術越受世界各國重視,本研究要探討製藥工業與生物技術產業間的關係,本研究的目的如下:
1.瞭解我國生物技術產業的發展與能力
2.分析我國製藥工業的環境及趨勢
3.探討生物技術在製藥工業應用上所帶來的影響
本研究以深入訪談相關學者及產業專家和收集相關產業資料為主,分析生物技術對製藥工業的適用性、價值與應用範圍,再以Michael Porter之鑽石理論架構來找出生物技術對製藥工業的影響及關係。
研究結果
(一)就我國生物技術的現況和能力
1.從市場需求的觀點,生物技術將是我國未來科技必須發展的關鍵科技。
2.我國現有足夠的基礎研發能力,可支持發展生物技術相關產業。
3.我國在上、中、下游的前瞻性研發、研發應用及商品化之技術的能力不足,急需建立。
(二)就我國製藥工業的現況和趨勢
1.生技相關藥品是一個藥品發展的國際趨勢,台灣必須引進生物技術來維持及提昇我國的製藥工業。
2.在台灣成長緩慢的製藥工業,引進新技術可擴大市場需求。
3.我國的藥品市場不足以維持製藥工業在研發上的規模經濟。
(三)生物技術引進製藥工業所帶來的影響
1.生物技術可提升製藥工業的產率、成本、速率和品質。
2.製藥工業引進生物技術可改善現有研發能力。
3.生物技術可為製藥工業帶來更多的知識及技術支持。
4.生物技術可為製藥工業創造更多的市場需求。
5.生物技術產業的發展是可由生物技術的導入製藥工業而相輔相成。
6.引進生物技術是我國製藥工業在未來需保有競爭優勢條件之一。
7.引進生物技術是確保我國製藥工業能在未來擁有掌握市場機會的能力。
Abstract
Recent discoveries in biotechnology are propelling exciting and revolutionary advances in pharmaceutical industry especially in the research and development process. This research aims to study the competitive analysis of applying biotechnology in pharmaceutical industry following the “Diamond Model” proposed by Michael Porter in The Competitive Advantage of Nations. Chapter Four and Five will devote in presenting the current conditions of biotechnology and pharmaceutical industries respectively including their characteristics and market developments. Lastly, Chapter Six will focus on the application analysis of biotechnology in pharmaceutical industry in Taiwan.
First, this research has revealed that both the domestic and global demands on bio-pharmaceutical products are great, but the small domestic market can not support the economies of scale of the heavy R&D operation characteristic of this industry. Second, opportunities in bio-pharmaceuticals have emerged with FDA lessening on the approval regulations on botanical drug products and expiration of drug patents, but Taiwan is either unable or slow to capitalize on these opportunities. Third, the domestic abilities in fundamental R&D as well as the quality of human resources can support the down-stream operations of pharmaceutical industry but weak in the pioneering and innovative technology research. Also, biotechnology and pharmaceutical industries are asserting “pulling effect” on each other but venture capital firms assume an important role in providing the initial funding to start-ups enterprises. In addition, although the lack of intense domestic rivals can’t drive the development and innovation in domestic bio-pharmaceutical industry, most domestic companies have followed the global trends and sought international strategic partners. Lastly, with the government support the risk in investing in domestic bio-pharmaceutical industry is greatly reduced.
In conclusion, since applying biotechnology in pharmaceutical industry can reduce production time and cost while increasing the quality and efficiency, biotechnology revolutionizes the drug formulation process and broadens the scope of drug targets. Biotechnology can not only increase the competitiveness of our pharmaceutical industry but also capture the great potential brought about by this disruptive technology. This global trend creates new demands both domestically and globally. Since this industry does not emphasize on vertical integration but rather on division of labor, globally competitive strategic partners are crucial for survival. Most importantly, more capital resources and efforts still must be devoted into promoting and developing this industry and improving the domestic environment conditions.
Acknowledgmentsi
Abstractii
Table of Contentsiv
List of Tablesvi
List of Figuresviii
Chapter 1 Introduction 1
I.The Research Background and Motive1
II.The Research Purpose4
Chapter 2 Literature Review5
I.Definition and Research Fields in Biotechnology Industry5
II.Impact of New Technology on Competitive Advantage7
III.Industry Analysis9
A.The Competitive Advantage of Nations9
B.The Five Forces Model of Industry Attractiveness12
Chapter 3 Research Methodology15
I.The Conceptual Framework of Research15
II.The Research Procedure16
III.The Limitation of this Research19
Chapter 4 The Present Development of Biotechnology Industry in Taiwan20
I.The Characteristics of Biotechnology Industry and Key Technologies20
II.The Current State of Biotechnology Industries Worldwide24
III.The Current State of Biotechnology Industry in Taiwan28
A.The Coordination of Biotechnology Research29
B.The Funding of Biotechnology Research31
C.The Performance of Biotechnology Industry33
D.The Comparison of Taiwan’s Biotechnology Industry with Other Major Countries35
Chapter 5 The Present Development of Pharmaceutical Industry in Taiwan36
I.The Characteristics of Pharmaceutical Industry36
II.The Current State of Pharmaceutical Industry in Taiwan40
III.The Problems of Domestic Pharmaceutical Industry 48
Chapter 6 The Analysis of Applying Biotechnology in Domestic Pharmaceutical Industry53
I.The Appropriateness of Applying Biotechnology in Pharmaceutical Industry53
II.The Value of Applying Biotechnology in Pharmaceutical Industry57
III.The Scope of Applying Biotechnology in Pharmaceutical Industry62
IV.The Competitive Advantage Analysis69
A.Demand Conditions69
B.Chance74
C.Factor Conditions77
D.Related and Supporting Industries83
E.Strategy, Structure, and Rivalry91
F.Government94
Chapter 7 The Conclusions and Suggestions102
I.The Research Conclusions102
II.The Suggestions for Further Research108
References 109
Appendix I The Government Incentives Program114
Appendix IIThe List of Companies in Science-Based Industrial Parks126
Appendix IIIThe Websites Useful to This Research128
1.“The Biotech Boom,” Newsweek, Oct 30, 2000. pp.46-52.
2.“The Pharmaceutical Industry,” The Economics, February 21st, 1998.
3.Ansoff, H.I. and E. J. McDonnell. Implanting Strategic Management, Prentice Hall, 3rd Edition, 1990.
4.Barley, S., Freeman, J. and Hybels R. “Strategic Alliances in Commercial Biotechnology,” Networks and Organizations, Chapter 12. 1992.
5.Besanko, Dranove and Shanley. Economics of Strategy. John Wiley & Sons, Inc., New York, 2nd Edition, 2000.
6.Biotechnology/Pharmaceutical Industries Semimonthly, MOEA. Vol. 64, No. 64, 5, 15, 2001. pp. 2-5.
7.Biotechnology: Theory and Applications 1993. Proceeding of the Third Pacific Rim Biotechnology Conference, August, 1992.
8.Bower, J. L. and Christensen, C. M. “Disruptive Technologies: Catching the Wave,” Harvard Business Review, January-February, 1995. pp.43-53.
9.Craig, A. M. and Malek, M. O. “Market Structure and Conduct in the Pharmaceutical Industry,” Pharmaceutical Therapeutics. Vol. 66, 1995. pp. 301-337.
10.Deeds, D. et al. “Dynamic Capabilities and New Product Development in High Technology Ventures: An Empirical Analysis of New Biotech Firms,” Journal of Business Venturing, 1999. pp. 211-229.
11.Hensley et al. “Celera Is Expected to Unveil DNA Map,” Asia Wall Street Journal, 5, 30, 2000.
12.Hensley, S. “Genome Map Opens Path to Drug,” Asia Wall Street Journal, 6, 27, 2000.
13.Humphrey, Arthur. “Some Issues in Biotechnology Commercialization,” Technology in Society. Vol. 18. No. 3. 1996. pp. 321-332.
14.Kirk, Niall. “The Emerging Biopharmaceutical Sector in Germany, 1993, ” Bio/technology, No. 500, 1993. pp.10-13.
15.Lerner, J. and Merges, R. “The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry,” Journal of Industrial Economics, 1998. pp. 125-156.
16.Pharmaceutica Acta Helvetiae. “Research and Development of Vaccines and Pharmaceuticals from Biotechnology.” Elsevier Science, 1997.
17.Pharmaceutical Research and Manufacturers of America. PhRMA Annual Survey─Pharmaceutical Industry Profile 2000, 2000.
18.Pisano, G., Shan, W. and Teece, D. “Joint Ventures and Collaboration in the Biotechnology Industry,” International Collaborative Ventures in U.S. Manufacturing, Chapter 6, 1988.
19.Pitts, Robert A and Lei, David. Strategic Management. South-Western College Publishing, USA, 2nd Edition, 2000.
20.Porter, Michael E., The Competitive Advantage of Nations, Mori, 1996.
21.Powell, W. “Learning from Collaboration: Knowledge & Networks in the Biotech and Pharm Industries,” California Management Review, 1998.
22.Prentis, Steve. Biotechnology: A New Industrial Revolution. George Braziller, Inc., New York, 1984.
23.Saviotti, P. “Industrial Structure & Dynamics of Knowledge Generation in Biotechnology,” Biotechnology and Competitive Advantage, Chapter 3, 1998.
24.Shan, W., Walker, G. and Kogut, B. “Inter-firm Cooperation and Startup Innovation in the Biotechnology Industry,” Strategic Management Journal, Vol. 15, 1994. pp. 387-394.
25.Solleiro, J. “Intellectual Property Rights and the Growth of Biotechnology-Based Industries in Developing Countries,” Biotechnology Advances, 1997. pp. 565-582.
26.Spalding, B. J. “How Biotechnology is Framing as an Industry,” Chemical Week, Vol. 139, Issue 23, pp. 9-13, 1986, Dec.
27.Su, Yuan-Chi. “Current Status of Biotechnology Research and Development in Taiwan.” Bioindustry, Vol. 1, No. 2, pp.160-170, 1990.
28.WD生物科技研討會,2000年12月21日。
29.生物技術開發中心IT IS計畫,生物技術服務業現況與趨勢,2000年10月。
30.生物技術開發中心IT IS計畫,生物技術產業年鑑2000,2000年9月。
31.生物技術開發中心IT IS計畫,生物技術/製藥產業之現況與趨勢─回顧1999展望2000,2000年1月。
32.生物技術開發中心IT IS計畫,台灣製藥產業(1998/1999),1999年7月。
33.生物技術產業推展研討會論文集,1998年6月24日。
34.田蔚城,生物技術導論,Bioindustry, Vol. 8, No. 1, 1997。
35.田蔚城主編,生物技術,九州圖書文物有限公司,1996年2月。
36.行政院科技顧問組,”行政院第四次生物技術產業策略報告,” 生物產業, Vol. 11 No. 2, 2000。
37.巫文玲,“大陸中藥產業現況,” 生物產業, Vol. 10 No. 3, 1999.
38.林秀琴,台灣生技走向策略聯盟,財訊快報,2000年5月22日。
39.范江哲寶, “基亞生技抗癌新藥未演先轟動,” 商業週刊,2000年9月18日。
40.范淑珍,透視華爾街生化科技股,商周出版社,2000。
41.財訊,“獨家專訪「台灣醫界之寶」許世明”,2001年2月。
42.財團法人生物技術開發中心,台灣製藥產業升級政策面面觀,中華民國製藥發展協會第三屆第一次會員代表大會,1996年7月19日。
43.財團法人生物技術開發中心,生物產業與製藥產業,九州圖書文物有限公司,1999年1月。
44.涂可欣、李千毅(譯),金色雙螺旋,天下文化出版,1995。
45.國科會,中華民國科學技術年鑑,2000。
46.基因改造食品之貿易管理檢驗與標示問題研討會論文集,2000年11月7日。
47.基因轉殖生物相關議題研討會論文集,2000年6月。
48.曹國維(譯),生物科技大未來,麥格爾、希爾出版,2000。
49.陳來明,我國生物技術產業分析-資源基礎觀點,國立政治大學科技管理研究所碩士論文,1996年7月。
50.陳恆德,“如何提昇國內新藥臨床試驗水準,” 生物產業, Vol. 11 No. 1, 1999.
51.陳昶安,我國製藥農業採用生物技術之影響因素探討,國立交通大學經營管理研究所碩士論文,1999年6月。
52.陳懷瑜等, “台灣生技產業發展現況”,卓越雜誌,2000年10月。
53.楊惠吉,我國生物技術在食品工業應用之探討,國立中興大學企業管理研究所碩士論文,1999年6月。
54.章曉梅 (2000) “健亞生技個案,” 中衛簡訊, vol. 144, pp.52-55.
55.經濟部工業局,行政院 「加強生物技術產業推動方案」八十九年第四季執行成果,2001年3月5日。
56.黎耀基,“我國生物科技產業與生技人才培育,” 科學發展月刊,第29卷 第5期, pp. 307-313.
57.盧燕俐, “中橡轉投資孤兒藥”、“五鼎生技”、 “邦拓生技”、 “統一生命科技”、 “仁山生技”,今週刊,2000年5月7日。
58.謝宏媛,“沈燕士帶領五鼎,闖生技先鋒,” 遠見雜誌,2001年6月1日。
59.蕭副家, “生物技術21世紀明星產業,” 財訊快報,2000年5月25~27日。
60.蘇遠志,生物技術產業國內現況與世界市場發產趨勢,生物醫學報導 第一期,台灣大學生物技術研究中心,2000年5月1日。
61.蘇遠志、李昆達,“日本植物生物科技及中草藥研究發展之現況,” 生物產業, Vol. 11 No. 3, 2000.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top